Innate Pharma (IPHA) Income towards Parent Company (2020 - 2024)
Historic Income towards Parent Company for Innate Pharma (IPHA) over the last 5 years, with Q4 2024 value amounting to -$52.9 million.
- Innate Pharma's Income towards Parent Company fell 54905.28% to -$52.9 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$61.0 million, marking a year-over-year decrease of 64365.26%. This contributed to the annual value of -$133652.4 for FY2022, which is 9845.94% up from last year.
- Latest data reveals that Innate Pharma reported Income towards Parent Company of -$52.9 million as of Q4 2024, which was down 54905.28% from -$8.1 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Income towards Parent Company ranged from a high of -$59145.8 in Q4 2022 and a low of -$75.3 million during Q4 2020
- For the 5-year period, Innate Pharma's Income towards Parent Company averaged around -$37.7 million, with its median value being -$52.0 million (2021).
- As far as peak fluctuations go, Innate Pharma's Income towards Parent Company surged by 9988.63% in 2022, and later crashed by 1367083.18% in 2023.
- Quarter analysis of 5 years shows Innate Pharma's Income towards Parent Company stood at -$75.3 million in 2020, then soared by 30.91% to -$52.0 million in 2021, then skyrocketed by 99.89% to -$59145.8 in 2022, then crashed by 13670.83% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024.
- Its Income towards Parent Company stands at -$52.9 million for Q4 2024, versus -$8.1 million for Q4 2023 and -$59145.8 for Q4 2022.